The goal of this clinical trial is to learn if the use of dose-escalated MRI-guided irradiation increases the rates of disease control in patients with pancreatic cancer
Selection criteria includes patients with unresectable and borderline resectable and medically inoperable pancreatic cancer that will receive neoadjuvant chemotherapy followed by chemoirradiation.
No prior radiation therapy to the target areas;
Karnofsky performance status > 70 with medical condition not contraindicating treatment with radical intent including neoadjuvant chemotherapy followed by chemoirradiation.
WBC equal or greater than 3500 mm^3; platelet count equal or greater than 135000 mm^3; hemoglobin equal or greater than 10 gr/L; BUN equal or less than 20; serum creatinine equal or less than 2.0.
Inability to undergo an MRI scan
Single group
MR-guided Irradiation
RadiationMR-guided Irradiation
Overall Survival
A. To achieve a 1-year survival of 85%.
Adverse Events
To decrease grade 4-5 gastrointestinal events to less than 5%.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
